| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Antibody-mediated pathogenesis of chronic GVHD through DBY/HLA class II complexes and induction of a GVL effect
|
Umino, Kento
|
|
|
142 |
11 |
p. 1008-1021
|
artikel
|
| 2 |
Back Matter
|
|
|
|
142 |
11 |
p. I
|
artikel
|
| 3 |
Chemoresistance pathways in DLBCL
|
Deaglio, Silvia
|
|
|
142 |
11 |
p. 943-944
|
artikel
|
| 4 |
CLL patients: GIVe me three!
|
Kwok, Marwan
|
|
|
142 |
11 |
p. 941-943
|
artikel
|
| 5 |
De Bruyne E, Bos TJ, Schuit F, et al. IGF-1 suppresses Bim expression in multiple myeloma via epigenetic and posttranslational mechanisms. Blood. 2010;115(12):2430-2440.
|
|
|
|
142 |
11 |
p. 1027
|
artikel
|
| 6 |
DLBCL-associated NOTCH2 mutations escape ubiquitin-dependent degradation and promote chemoresistance
|
Zhou, Nan
|
|
|
142 |
11 |
p. 973-988
|
artikel
|
| 7 |
Double trouble: IRAK1/4 inhibitors in AML/MDS
|
Uckelmann, Hannah J.
|
|
|
142 |
11 |
p. 945-946
|
artikel
|
| 8 |
Editorial Board
|
|
|
|
142 |
11 |
p. xiii
|
artikel
|
| 9 |
Fibrin-associated large B-cell lymphoma shows frequent mutations related to immune surveillance and PTEN
|
Boyer, Daniel F.
|
|
|
142 |
11 |
p. 1022-1025
|
artikel
|
| 10 |
Final analysis of the CLL2-GIVe trial: obinutuzumab, ibrutinib, and venetoclax for untreated CLL with del(17p)/TP53mut
|
Huber, Henriette
|
|
|
142 |
11 |
p. 961-972
|
artikel
|
| 11 |
How I treat non-transfusion-dependent β-thalassemia
|
Saliba, Antoine N.
|
|
|
142 |
11 |
p. 949-960
|
artikel
|
| 12 |
Hu J, Dang N, Menu E, et al. Activation of ATF4 mediates unwanted Mcl-1 accumulation by proteasome inhibition. Blood. 2012;119(3):826-837.
|
|
|
|
142 |
11 |
p. 1027
|
artikel
|
| 13 |
Masthead Subscription
|
|
|
|
142 |
11 |
p. IFC
|
artikel
|
| 14 |
Paralog-specific signaling by IRAK1/4 maintains MyD88-independent functions in MDS/AML
|
Bennett, Joshua
|
|
|
142 |
11 |
p. 989-1007
|
artikel
|
| 15 |
Table of Contents
|
|
|
|
142 |
11 |
p. xi-xii
|
artikel
|
| 16 |
Unexpected parvovirus B19 infection in a patient with multiple myeloma
|
Li, Julie Y.
|
|
|
142 |
11 |
p. 1026
|
artikel
|
| 17 |
W“H-Y” antigen/HLA complexes in chronic GVHD
|
Holtzman, Noa G.
|
|
|
142 |
11 |
p. 946-948
|
artikel
|
| 18 |
Williams AM, Salehabadi SM, Xing M, et al. Modifiable risk factors for neurocognitive and psychosocial problems after Hodgkin lymphoma. Blood. 2022;139(20):3073-3086.
|
|
|
|
142 |
11 |
p. 1028
|
artikel
|
Tijdschrift beschrijving